

# ANTH CRAN \*

## New & more bioavailable cranberry extract

Serena Tongiani, Chief Product Portfolio Indena Spa serena.tongiani@indena.com



## SCIENCE IS OUR NATURE. SINCE 1921





10-12 May 2022 Geneva 2-13 May 2022 Online



#### A urinary tract infection (UTI) can affect any part of the urinary system, kidneys, bladder or urethra.

More than 150 million people globally suffer from urinary tract infections, and about 30% will have a recurrent infection within 6 months. mostly women. Symptoms include frequent, painful urination, pelvic pain and traces blood in the urine.



https://emedprimarycare.com/urinary-tract-infections/ Emed Jacksonville, Florida





#### **CRANBERRY** (Vaccinium macrocarpon) **EXTRACT**

The cranberry is one of the most thoroughly studied foods for the prevention of urinary tract infections. It is a rich source of polyphenols, including the unique Atype proanthocyanidins, but is now an evidence that the activity goes beyond the PAC content

For a UTI to occur, bacteria must adhere to and invade the lining of the bladder. Cranberries extract contains specific compounds which interfere with the bacteria's ability to the bladder wall, reducing the likelihood of infection.



![](_page_1_Picture_10.jpeg)

![](_page_1_Picture_11.jpeg)

![](_page_2_Picture_0.jpeg)

### 1994

The first randomized, double-blind, placebo-controlled clinical trial investigating the treatment and preventative effects of cranberry juice in bacteriuria and pyuria

#### 1984

Cranberry juice reported to inhibit the adherence of *E. coli* and other gram-negative bacteria to epithelial cells.

#### 1905

Topical use of cranberry noted by *King's American Dispensatory* to ameliorate inflammation, swelling, and ulcers

### 1801

Cranberries introduced into American medical practice as an anti-scorbutic, laxatic, and anti-pyretic

![](_page_2_Picture_9.jpeg)

#### 1998

Addition of cranberry to growth medium of P-fimbriated *E. coli* causes loss of adhesion and loss of fimbriae correlated with incubation time

### 2000

The structureofcranberryproanthocyanidins(PACs)aredescribed in detail

**2020** NEW ACTIVE METABOLITES IDENTIFIED AFTER ANTHOCRAN® INTAKE

**Pre-1800s** 

First anecdotal medical use of cranberries associated with Native American tribes

![](_page_2_Picture_18.jpeg)

![](_page_2_Picture_19.jpeg)

# ANTH CRAN \*

## FULL PHYTOCHEMICAL CHARACTERIZATION

![](_page_3_Picture_2.jpeg)

![](_page_3_Picture_3.jpeg)

## INDENA EXPERTISE AT THE SERVICE OF QUALITY AND INNOVATION

**CONCENTRATED JUICE** 

Shipment at – 20°C

![](_page_4_Picture_1.jpeg)

![](_page_4_Picture_2.jpeg)

#### **APPLICATION OF PHYTOSOME® TECHNOLOGY**

![](_page_4_Picture_4.jpeg)

![](_page_4_Picture_5.jpeg)

INDENA CRANBERRY EXTRACT MAINTAINS THE SAME PHYTOCHEMICAL PROFILE OF NATURAL CRANBERRY JUICE

![](_page_4_Figure_7.jpeg)

![](_page_4_Picture_9.jpeg)

![](_page_5_Picture_0.jpeg)

## THE FULL SPECTRUM OF POLYPHENOLS

![](_page_5_Picture_2.jpeg)

![](_page_5_Picture_3.jpeg)

#### FLAVONOLS, FLAVANOLS AND PACs

Scopoletin Kaempferol Epicatechin Catechin Quercetin Epigallocatechin Gallocatechin Isorhamnetin Myricetin 3'-O-methylmyricetin Syringetin Quercetin-3-O-arabinofuranoside Quercetin-3-O-arabinopyranoside Quercetin-3-O-xylopyranoside Catechin-3-O-gallate Epicatechin-3-O-gallate Kaempferol-7-O-glucoside Isorhamnetin-3-O-arabinofuranoside Isorhamnetin-3-O-xylopyranoside Isorhamnetin-3-O-arabinopyranoside Quercetin-3-O-rhamnoside Myricetin-3-O-arabinofuranoside Myricetin-3-O-arabinopyranoside Myricetin-3-O-xylopyranoside Quercetin 3-O-glucoside Quercetin-3-O-galactoside Isorhamnetin-3-O-glucopyranoside Isorhamnetin-3-O-glucofuranoside Isorhamnetin-3-O-galactoside Syringetin-3-O-arabinofuranoside Syringetin-3-O-xylopyranoside Syringetin-3-O-arabinopyranoside Myricetin-3-O-glucoside Myricetin-3-O-galactoside Syringetin-3-O-rhamnoside Proanthocyanidin A-type dimer Proanthocyanidin B-type dimer Proanthocyanidin A-type trimer Proanthocyanidin B-type trimer

#### **ANTHOCYANINS**

Cyanidin Peonidin Cyanidin-3-O-arabinoside Peonidin-3-O-arabinoside Cyanidin-3-O-galactoside Cyanidin-3-O-glucoside Petunidin-3-O-galactoside Peonidin-3-O-galactoside Malvidin-3-O-galactoside Malvidin-3-O-glucoside

#### **PHENOLIC ACIDS**

Benzoic acid Protocatechuic acid p-Coumaric acid Gallic acid Caffeic acid Ferulic acid Sinapinic acid Caffeoyl glucose Chlorogenic acid

![](_page_5_Picture_10.jpeg)

CONTAINS THE FULL POLYPHENOLS PROFILE OF NATURAL CRANBERRY, NOT ONLY PACs

![](_page_5_Picture_14.jpeg)

![](_page_6_Picture_0.jpeg)

![](_page_6_Picture_1.jpeg)

New health-food ingredient based on the formulation of

Standardized in proanthocyanidins: 6.0-9.0% UV-visible spectrophotometric contents (DMAC method).

Suggested dose: 120 mg/day

![](_page_6_Picture_5.jpeg)

![](_page_6_Picture_6.jpeg)

![](_page_6_Picture_7.jpeg)

CRANBERRY (Vaccinium macrocarpon) EXTRACT

![](_page_6_Picture_10.jpeg)

# proprietary cranberry extract Anthocran with Phytosome<sup>®</sup> technology.

![](_page_6_Picture_12.jpeg)

![](_page_6_Picture_13.jpeg)

![](_page_6_Picture_14.jpeg)

#### **INDENA TECHNOLOGY TO IMPROVE** BIOAVAILABILITY

#### **HEALTH FOOD** INGREDIENT

![](_page_6_Picture_18.jpeg)

Indena

## NATURAL INGREDIENT

Health benefits

Inhibition of self-aggregation

Phytosome<sup>®</sup> is a solid dispersion of botanicals or natural compounds into a 100% food-grade matrix based on lecithin, amphipathic molecules which act as inhibitor of self-aggregation and effective wetting agents.

![](_page_7_Picture_4.jpeg)

# THE BIOMIMETIC DELIVERY SYSTEM

## OPTIMIZED ORAL BIOAVAILABILITY OF NATURAL INGREDIENTS

LECITHIN

## 3

### FOOD ADDITIVES

Improvement of technological properties (e.g. density, flowability)

![](_page_7_Picture_12.jpeg)

# ANTH& CRAN \*

## CRANBERRY EXTRACT

SUNFLOWER LECITHIN

MANUFACTURING SOLVENT: ETHYL ACETATE

![](_page_8_Picture_4.jpeg)

## **LOSSONCE** THE BIOMIMETIC DELIVERY SYSTEM

## OPTIMIZED ORAL BIOAVAILABILITY OF NATURAL INGREDIENTS

![](_page_8_Figure_7.jpeg)

![](_page_8_Picture_9.jpeg)

# ANTHOCKAR THE ROAD MAP

2

#### **URINARY HUMAN PHARMACOKINETICS**

**NEW PACs METABOLITES FIRSTLY DESCRIBED IN HUMAN URINE** 

![](_page_9_Picture_3.jpeg)

**FORMULATION DESIGN** 

![](_page_9_Picture_5.jpeg)

3

![](_page_9_Picture_7.jpeg)

#### **INTERACTION WITH** HUMAN MICROBIOTA

**EVIDENCE OF POSITIVE INTERACTIONS WITH CRANBERRY POLYPHENOLS** 

#### **PREVENTION OF RECURRENT UTIS AFTER** CATHETERIZATION

**HUMAN EFFICACY STUDY** 

![](_page_9_Picture_12.jpeg)

4

![](_page_9_Picture_14.jpeg)

![](_page_9_Figure_15.jpeg)

![](_page_10_Picture_0.jpeg)

# HUMAN URINEPKSTUDY

![](_page_10_Picture_2.jpeg)

![](_page_10_Picture_3.jpeg)

![](_page_11_Picture_0.jpeg)

## HUMAN URINE PK STUDY

## INGREDIENTS MEANT TO TREAT URINARY TRACT INFECTIONS (UTIs) NEED TO BE FOUND IN THE URINE RATHER THAN IN THE PLASMA

Biochemical Pharmacology 173 (2020) 113726

Contents lists available at ScienceDirect

**Biochemical Pharmacology** 

journal homepage: www.elsevier.com/locate/biochempharm

Profiling *Vaccinium macrocarpon* components and metabolites in human urine and the urine *ex-vivo* effect on *Candida albicans* adhesion and biofilmformation

Giovanna Baron<sup>a</sup>, Alessandra Altomare<sup>a</sup>, Luca Regazzoni<sup>a</sup>, Laura Fumagalli<sup>a</sup>, Angelica Artasensi<sup>a</sup>, Elisa Borghi<sup>b</sup>, Emerenziana Ottaviano<sup>b</sup>, Cristian Del Bo<sup>c</sup>, Patrizia Riso<sup>c</sup>, Pietro Allegrini<sup>d</sup>, Giovanna Petrangolini<sup>d</sup>, Paolo Morazzoni<sup>d</sup>, Antonella Riva<sup>d</sup>, Lolita Arnoldi<sup>d</sup>, Marina Carini<sup>a</sup>, Giancarlo Aldini<sup>a</sup>,\*

- <sup>a</sup> Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via Luigi Mangiagalli 25, 20133 Milan, Italy
- <sup>b</sup> Department of Health Sciences, Università degli Studi di Milano, Via Di Rudinì 8, 20142 Milan, Italy
- <sup>c</sup> Department of Food, Environmental and Nutritional Sciences, Università degli Studi di Milano, Via Luigi Mangiagalli 25, 20133 Milan, Italy
- <sup>d</sup> Indena S.p.A, Viale Ortles 12, 20139 Milan, Italy

![](_page_11_Picture_13.jpeg)

![](_page_11_Picture_15.jpeg)

![](_page_11_Picture_16.jpeg)

![](_page_11_Picture_17.jpeg)

![](_page_11_Picture_18.jpeg)

## **STUDY DESIGN AND OBJECTIVES**

![](_page_12_Figure_1.jpeg)

- **STUDY DESIGN:** randomized, cross-over, double-blind
- **POPULATION:** 13 healthy volunteers (**women**, age 25±4 years, BMI 26.6±2.0 kg/m<sup>2</sup>)
- FORMULATION A:

120 mg (=**36 mg** of PACs)

- FORMULATION B: ANTHOCRAN® 120 mg (=9 mg of PACs)
- **SAMPLING:** day 0 and day 7 (at 1, 2, 4, 6, 10, 12, 24h)

### **STUDY ENDPOINTS:**

#### **#1 FULL IDENTIFICATION OF CRANBERRY COMPOUNDS AND METABOLITES IN URINE**

- Which cranberry components are found in urine?
- Do proanthocyanidins (PACs) reach the urine?
- If not, what is responsible for cranberry-acknowledged health benefits in UTIs?

#### **#2 ACTIVITY AGAINST CANDIDA ALBICANS**

- Is Anthocran<sup>®</sup> Phytosome<sup>®</sup> effective against adhesion and biofilm formation of *Candida albicans* clinical isolates (*Ex vivo effect*)?
- Is Anthocran Phytosome<sup>®</sup> as effective as Anthocran<sup>®</sup>, despite the lower content of PACs (9 mg vs. 36 mg) in the same unitary dose?

![](_page_12_Picture_17.jpeg)

## THE **RIGHT** PK STUDY: **POLYPHENOL PROFILE IN HUMAN URINE** A DEEP, DOUBLE INVESTIGATION WITH 2 DIFFERENT METHODS ALLOWED FOR THE **IDENTIFICATION OF 42 COMPOUNDS IN HUMAN URINE, INCLUDING NEW ONES**

Sinapinic acid

#### **TARGETED ANALYSIS**:

searching in urine samples for the compounds listed in an inhouse database (total number of compounds = 138)

Targeted

3,4-dihydroxyhydrocinnamic acid Protocatechuic acid p-Coumaric acid Gallic acid Kaempferol Quercetin Syringetin Quercetin-3-O-arabinofuranoside Quercetin 3-O-rhamnoside Quercetin-3-O-galactoside 2-hydroxybenzoic acid 3-hydroxybenzoic acid 4-hydroxybenzoic acid 2,3-dihydroxybenzoic acid 2,5-dihydroxybenzoic acid 2,4-dihydroxybenzoic acid 3-(4-hydroxyphenyl)-propionic acid 3,4-dihydroxyphenylacetic acid Hippuric acid Isorhamnetin-3-O-arabinopyranoside 4-methylcatechol-O-sulphate Pyrogallol-O-2-sulphate Vanillic acid-4-O-sulphate

![](_page_13_Picture_5.jpeg)

p-Hydroxyhippuric acid m-Hydroxyhippuric acid o-Hydroxyhippuric acid (salicyluric acid) 5-(3',4'-dihydroxyphenyl)-y-valerolactone 5-(3',4'-dihydroxyphenyl)-y-valerolactone-4'-O-sulphate Dihydroxyhydrocinnamic acid-3-O-glucuronide Quinic acid 2-methylhippuric acid 5-(3',4'-dihydroxyphenyl)-y-valerolactone-3'-O-sulphate 5-(3',4',5'-trihydroxyphenyl)-y-valerolactone-3'-O-sulphate 4-Hydroxy-5-(dihydroxyphenyl)-valeric acid-O-sulphate Salicyluric glucuronide 3-O-Methylcatechin-sulphate 5-(3',4'-dihydroxyphenyl)-y-valerolactone-3'-O-glucuronide 5-(3',4'-dihydroxyphenyl)-y-valerolactone-4'-O-glucuronide Sinapinic glucuronide 5-(3',4'-dihydroxyphenyl)-y-valerolactone sulphoglucuronide

Untargeted

#### **UNTARGETED ANALYSIS:**

searching for ions present in urine samples collected after cranberry consumption, that were not present in the pretreatment sample (MS/MS)

![](_page_13_Figure_9.jpeg)

![](_page_13_Figure_10.jpeg)

# **IDENTIFICATION OF COMPOUNDS FIRST DESCRIBED IN HUMAN URINE**

### **ANTHOCRAN TREATMENT LEADS TO THE IDENTIFICATION OF COMPOUNDS RESPONSIBLE FOR CRANBERRY-ACKNOWLEDGED CLINICAL EVIDENCE IN UTIS**

PACs (A and B type)

**NOT DETECTED** 

**ANTHOCYANINS** 

LACK OF DETECTION

**FLAVONOLS** 

LOW ABOUNDANCE OF **GLYCOSYLATED FORMS** 

VALEROLACTONES AND VALERIC **ACIDS** 

**IDENTIFIED IN HUMAN URINE FOR THE FIRST** TIME

![](_page_14_Picture_10.jpeg)

A-type are considered to be related to cranberry activity in UTIs, but evidence for this in the literature is inconclusive

Lack of detection in urine is in agreement with literature

Degraded into phenolic compounds by human microbiota in the colon

Possible biotransformation mediated by colonic microflora into small phenolic compounds

Low abundance of glycosylated forms due to enzymatic hydrolysis into corresponding aglycones, taking place in the intestine

Aglycones can be transformed into phenolic acids by C-ring cleavage and/or undergo phase-II metabolism

Known as PACs metabolites, but never identified in urine after cranberry intake

**Reports suggest that the biotransformation of PACs to valerolactones is** driven by gut microbiota

![](_page_14_Picture_22.jpeg)

![](_page_14_Picture_23.jpeg)

![](_page_15_Picture_0.jpeg)

## INTERACTION WITH HUMAN MICROBIOTA

![](_page_15_Picture_2.jpeg)

![](_page_15_Picture_3.jpeg)

![](_page_16_Picture_0.jpeg)

# **EX VIVO STUDY DESIGN**

![](_page_16_Picture_2.jpeg)

#### **3 HEALTHY SUBJECTS**

(2

men and 1 woman):

- no antibiotics for previous 3 months
- no-polyphenols diet for 2 days prior to faecal collection

![](_page_16_Picture_7.jpeg)

**FAECAL SLURRY FERMENTED** FOR 24h WITH (samples standardized for PACs content):

extract

![](_page_16_Picture_10.jpeg)

![](_page_16_Picture_11.jpeg)

Bresciani, Letizia, et al. "In vitro (poly) phenol catabolism of unformulated-and phytosome-formulated cranberry (Vaccinium macrocarpon) extracts." Food Research International 141 (2021): 110137.

Food Research International 141 (2021) 110137

ELSEVIER

Contents lists available at ScienceDirect

FOOD research

Check for updates

Food Research International

journal homepage: www.elsevier.com/locate/foodres

#### In vitro (poly)phenol catabolism of unformulated- and phytosome-formulated cranberry (Vaccinium macrocarpon) extracts

Letizia Bresciani<sup>a, 1</sup>, Giuseppe Di Pede<sup>b, 1</sup>, Claudia Favari<sup>b</sup>, Luca Calani<sup>c</sup>, Veronica Francinelli<sup>b</sup>, Antonella Riva<sup>d</sup>, Giovanna Petrangolini<sup>d</sup>, Pietro Allegrini<sup>d</sup>, Pedro Mena<sup>b,\*</sup>, Daniele Del Rio<sup>a</sup>

<sup>a</sup> Department of Veterinary Science, University of Parma, Via Volturno, 39 - 43125 Parma, Italy Department of Food and Drug, University of Parma, Via Volturno, 39 - 43125 Parma, Italy partment of Food and Drug, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy Research and Development Department, Indena S.p.A., Viale Ortles, 12 – 20139 Milano, Italy

unformulated cranberry

#### **UHPLC-LIT-MS<sup>n</sup> ANALYSIS OF:**

 production of cranberry metabolites

![](_page_16_Picture_27.jpeg)

![](_page_17_Picture_0.jpeg)

## **PRODUCTION OF METABOLITES WITH BIOLOGICAL ACTIVITY**

![](_page_17_Figure_2.jpeg)

Propanoic acid derivatives Benzoic acid derivatives

![](_page_17_Picture_4.jpeg)

Unformulated Phytosomeformulated cranberry extract cranberry extract

![](_page_17_Picture_6.jpeg)

Anthocran<sup>®</sup> had significantly higher production of metabolites linked to phenylpropanoic and benzoic acid derivatives.

Anthocran Phytosome<sup>®</sup> in comparison could be metabolized slowly at colonic comparison to Anthocran<sup>®</sup>.

**Comparable concentration of metabolites after** 24 hrs suggests the Phytosome<sup>®</sup> does not interfere with physiological degradation.

![](_page_17_Figure_10.jpeg)

![](_page_17_Figure_11.jpeg)

## **UTIS: DON'T FORGET CANDIDURIA** (Candida albicans INFECTION)

#### FORMATION OF CANDIDA ALBICANS BIOFILMS

![](_page_18_Figure_2.jpeg)

Nature Reviews | Microbiology

Lohse, M., et al. Nat Rev Microbiol 16, 19–31 (2018). Gajdács, Márió, et al. Central European journal of urology 72.2 (2019): 209. Fisher, John F. " Clinical infectious diseases 52.suppl\_6 (2011): S429-S432.

![](_page_18_Picture_5.jpeg)

The presence of *Candida* spp. in urines (i.e. candiduria) is a common clinical finding increased considerably in recent years:

- frequent in **hospitalized patients**
- $\checkmark$  it can reach the **10% of positive urine cultures** in hospitals, intensive care units and tertiary care facilities
- major risk factors are indwelling urinary catheters, diabetes mellitus, V use of broad-spectrum antibiotics, urinary obstruction
- C. albicans is the most commonly reported species in urine culture

THE INCREASED RESISTANCE OF CANDIDA SPP. TO ANTIFUNGAL **AGENTS (e.g. FLUCONAZOLE) CALL FOR SAFE PREVENTIVE OR ADJUVANT INGREDIENTS AGAINST THE INFECTION** 

![](_page_18_Picture_13.jpeg)

![](_page_19_Picture_0.jpeg)

## **REDUCED CANDIDA ALBICANS ADHESION AND BIOFILM** FORMATION

![](_page_19_Figure_2.jpeg)

PACs 36 mg/cps

![](_page_19_Figure_4.jpeg)

![](_page_19_Figure_5.jpeg)

![](_page_19_Figure_6.jpeg)

![](_page_19_Picture_8.jpeg)

PACs 9 mg/cps

![](_page_19_Picture_10.jpeg)

WAS BIOEQUIVALENT TO UNFORMULATED CRANBERRY **EXT. DESPITE THE MUCH LOWER UNITARY DOSE OF PACs** (9 mg vs 36 mg).

*"GET THE SAME EFFECT WITH A LOWER CONTENT OF* **ACTIVE COMPOUNDS":** 

THE FAVOURABLE EFFECT OF PHYTOSOME® TECHNOLOGY

**ON PHYTOACTIVES ABSORPTION** 

![](_page_19_Picture_16.jpeg)

![](_page_20_Picture_0.jpeg)

## **REDUCED CANDIDA ALBICANS ADHESION AND BIOFILM** FORMATION

![](_page_20_Picture_4.jpeg)

![](_page_20_Figure_5.jpeg)

![](_page_20_Figure_6.jpeg)

![](_page_20_Figure_8.jpeg)

#### VALEROLACTONE DERIVATIVE

[5-(3',4'-dihydroxyphenyl)-γ-valerolactone] was the most abundant metabolite in the most bioactive fraction (12h)

![](_page_20_Picture_12.jpeg)

## **KEY MESSAGES FROM** THE **PK STUDY**

THE IN VIVO ACTIVITY OF **CRANBERRY EXTRACTS CAN BE ASSOCIATED WITH THE METABOLITES OF PACS (e.g.** valerolactones) **RATHER THAN PACs, WHICH IS** WHAT HAS BEEN ASSUMED SO FAR

![](_page_21_Picture_2.jpeg)

![](_page_21_Picture_4.jpeg)

![](_page_21_Picture_5.jpeg)

![](_page_21_Picture_6.jpeg)

**#1 NEW COMPOUNDS METABOLITES) HAVE BEEN IDENTIFIED IN HUMAN URINE** 

**#2 NEW PACs METABOLITES ARE THE MOST ACTIVE AGAINST PATHOGENIC ADHESION (Candida)** 

![](_page_21_Picture_9.jpeg)

![](_page_21_Picture_10.jpeg)

![](_page_22_Picture_0.jpeg)

## HUMAN STUDY IN URINARY TRACT INFECTIONS (UTIS)

![](_page_22_Picture_2.jpeg)

![](_page_22_Picture_3.jpeg)

![](_page_23_Picture_0.jpeg)

# **PROVEN EFFICACY IN PREVENTING UTIS**

JOURNAL OF DIETARY SUPPLEMENTS https://doi.org/10.1080/19390211.2021.1972074

ARTICLE

![](_page_23_Picture_4.jpeg)

**OPEN ACCESS** 

#### Anthocran<sup>®</sup> Phytosome<sup>®</sup>: Prevention of Recurring Urinary Infections and Symptoms after Catheterization

Roberto Cotellese<sup>a</sup>, Andrea Ledda<sup>b</sup>, Gianni Belcaro<sup>b,c</sup>, Maria R. Cesarone<sup>b,c</sup>, Claudia Scipione<sup>b</sup>, Valeria Scipione<sup>b</sup>, Mark Dugall<sup>b,c</sup>, Beatrice Feragalli<sup>a</sup>, Antonella Riva<sup>d</sup>, Pietro Allegrini<sup>d</sup>, Giovanna Petrangolini<sup>d</sup> D and Stefano Togni<sup>d</sup>

<sup>a</sup>Surgical School, G D'Annunzio University, Pescara, Italy; <sup>b</sup>Irvine3 Labs and San Valentino Vascular Screening Project DScMedBiotec, Chieti-Pescara University, Chieti, Italy; International Agency for Pharma Standard Supplements (IAPSS), Pescara, Italy; <sup>d</sup>R&D Indena SpA, Milan, Italy

![](_page_23_Picture_9.jpeg)

![](_page_23_Picture_11.jpeg)

#### Taylor & Francis

Taylor & Francis Group

Check for updates

![](_page_23_Picture_15.jpeg)

## **STUDY DESIGN**

![](_page_24_Figure_1.jpeg)

![](_page_24_Picture_2.jpeg)

#### **STUDY DESIGN:**

Open label, pilot, observational (registry)

#### **STUDY POPULATION:**

![](_page_24_Picture_6.jpeg)

n. 64 otherwise healthy subjects (BMI<26, ≈50 years of age, 29 women) with non-complicated surgery requiring catheterization during post-operative period because of history of recurrent UTIs (R-UTIs) or risk for UTIs (= at least 2 symptomatic UTIs in the previous year or 1 episode of UTI in the previous month)

![](_page_24_Picture_8.jpeg)

#### **STANDARD MANAGEMENT:**

Accurate hygiene (without local disinfectants); improved bladder care (drinking and voiding at appropriate time); reduced caffeine, spices and alcohol; careful hydration; mild exercise

![](_page_24_Picture_11.jpeg)

#### **PRIMARY ENDPOINTS:**

✤ Occurrence of urinary symptoms in the 4 weeks follow-up: frequency, dysuria, nacturia, urgency, pain

![](_page_24_Picture_14.jpeg)

#### **SECONDARY ENDPOINTS:**

- Presence of increased bacterial charge in urine
- Visible presence of blood in urine
- Need for consultation and specialist's evaluation

![](_page_24_Picture_19.jpeg)

![](_page_25_Picture_0.jpeg)

## **EFFECTIVE IN REDUCING UTIS SYMPTOMS**

![](_page_25_Figure_2.jpeg)

Cotellese, Roberto, et al. (2021)

![](_page_25_Picture_4.jpeg)

![](_page_25_Picture_5.jpeg)

### WAS SIGNIFICANTLY MORE EFFECTIVE IN REDUCING UTIS SIGNS AND SYMPTOMS, SHOWING A DOSE-RESPONSE:

- ✓ Lower urinary frequency
- ✓ Lower urinary urgency
  - Lower dysuria (=painful urination)
- ✓ Lower nocturia (=excessive urinating at night)
- ✓ Lower pain

 $\checkmark$ 

![](_page_25_Picture_12.jpeg)

![](_page_25_Picture_13.jpeg)

![](_page_26_Picture_0.jpeg)

## ACHIEVED ZERO INDIVIDUALS WITH:

![](_page_26_Figure_2.jpeg)

![](_page_26_Picture_3.jpeg)

![](_page_26_Figure_4.jpeg)

**URINES BACTERIAL CONTAMINATION** 

![](_page_26_Picture_6.jpeg)

![](_page_26_Figure_7.jpeg)

![](_page_26_Picture_9.jpeg)

![](_page_27_Picture_0.jpeg)

## **EFFECTIVE PREVENTION OF RECURRENT UTIS**

TREATMENT

STANDARD MANAGEMENT only

NITROFURANTOIN 150 mg/day

![](_page_27_Picture_5.jpeg)

![](_page_27_Picture_6.jpeg)

### **ACHIEVED ZERO SUBJECTS WITH RE-OCCURRENCE OF UTIS**

![](_page_27_Picture_9.jpeg)

Cotellese, Roberto, et al. (2021)

![](_page_27_Picture_11.jpeg)

#### **No. SUBJECTS WITH UTIS RE-OCCURRENCE IN THE 3 MONTHS FOLLOWING THE** TREATMENT (no. / total subjects)

3/18	(17%)			
4/22	(18%)			
0/12	(0%)			
0/12	(0%)			

#### **IN THE 3 MONTHS FOLLOWING TREATMENT**

![](_page_28_Picture_0.jpeg)

## TAKE HOME MESSAGES

![](_page_28_Picture_2.jpeg)

Exclusive Phytosome<sup>®</sup> technology optimizing phytoactives bioabsorption

Complete phytochemical profile investigation confirming the full polyphenols profile of natural cranberry

Deep investigation of human urine pharmacokinetics showing full polyphenolic profiles of cranberry phytoactives and metabolites

First report of PACs metabolites in human urine likely responsible of cranberry acknowledged health benefits

Clinical evidence in supporting urinary health and preventing recurrent UTIs

Superior clinical efficacy even with a lower content of PACs per unitary dose

Effective against pathogenic Candida albicans adhesion

![](_page_28_Figure_12.jpeg)

![](_page_29_Picture_0.jpeg)

See you at Stand E84

![](_page_29_Picture_5.jpeg)

![](_page_29_Picture_6.jpeg)

10-12 May 2022 Geneva 2-13 May 2022 Online

Indena.com

![](_page_29_Picture_9.jpeg)

![](_page_29_Picture_10.jpeg)